ENDOSTAR® is the commercial brand name of Recombinant human endostatin injection, a recombinant anti-angiogenic protein developed by Simcere Pharmaceutical. It inhibits endothelial cell proliferation and tumor angiogenesis, cutting off blood supply to tumor tissues and suppressing tumor growth.
Main Indications
Combined with NP chemotherapy regimen for the treatment of stage III/IV non-small cell lung cancer.
Clinical Research
Pivotal phase III clinical trial showed that ENDOSTAR plus NP chemotherapy significantly improved objective response rate and median time to progression compared with NP chemotherapy alone in patients with advanced non-small cell lung cancer, meeting the primary efficacy endpoint with acceptable safety profile.
Common Side Effects
Cardiac adverse reactions: arrhythmia, ST-segment changes;
Other common reactions: nausea, vomiting, fatigue, diarrhea, rash. Rare serious adverse events include severe cardiac toxicity and hemorrhage.
Approval Status in China
Original drug ENDOSTAR® (Recombinant Human Endostatin Injection) was officially approved for marketing in China in 2005. It is currently a prescription drug.
Buy ENDOSTAR (Recombinant Human Endostatin Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
